Mergers & Acquisitions ·
On August 21, 2026, Werewolf Therapeutics entered into an Agreement and Plan of Merger with Ambros Therapeutics
HOWLWerewolf Therapeutics, Inc.
On August 21, 2026, Werewolf Therapeutics entered into an Agreement and Plan of Merger with Ambros Therapeutics. Under the all-stock transaction, Ambros will merge into a wholly owned subsidiary of Werewolf, with pre-merger Ambros stockholders retaining approximately 71.7% ownership based on implied valuations of $500 million for Ambros and $47.5 million for Werewolf. Concurrently, Werewolf secured an oversubscribed private placement (PIPE) of $150 million to fund operations through the CRPS-RISE Phase 3 trial topline results in 2028 and planned NDA submission. The combined company will operate as Ambros Therapeutics under ticker AMBX on Nasdaq, focusing on neridronate for Complex Regional Pain Syndrome Type 1. Werewolf shareholders will retain approximately 6.8% ownership and receive contingent value rights related to legacy assets.